Advertisement
Advertisement
AYTU
AYTU BioPharma, Inc. Common Stock
2.71
USDSponsored
+0.06
+2.26%
Mar 25, 15:56 UTC -4
Closed
Pre-Market
2.63
-0.08
-3.09%
AYTU Earnings Reports
Positive Surprise Ratio
AYTU beat 21 of 37 last estimates.
57%
Next Report
Date of Next Report
May 12, 2026
Estimate for Q3 26 (Revenue/ EPS)
$13.31M
/-$0.57
Implied change from Q2 26 (Revenue/ EPS)
-12.21%
/-45.71%
Implied change from Q3 25 (Revenue/ EPS)
-27.85%
/-371.43%
AYTU BioPharma, Inc. Common Stock earnings per share and revenue
On Feb 03, 2026, AYTU reported earnings of -1.05 USD per share (EPS) for Q2 26, missing the estimate of -0.61 USD, resulting in a -71.57% surprise. Revenue reached 15.16 million, compared to an expected 12.42 million, with a 22.12% difference. The market reacted with a -10.31% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 5 analysts forecast an EPS of -0.57 USD, with revenue projected to reach 13.31 million USD, implying an decrease of -45.71% EPS, and decrease of -12.21% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Dyadic International, Inc.
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.04
Actual
-$0.06
Surprise
-30.72%
TELA Bio, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.18
Actual
-$0.16
Surprise
+14.12%
BioCardia, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.17
Actual
-$0.06
Surprise
+65.40%
Celcuity Inc. Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$1.06
Actual
-$0.97
Surprise
+8.72%
Precigen, Inc. Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.08
Actual
-$0.01
Surprise
+88.24%
Absci Corporation Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.19
Actual
-$0.23
Surprise
-16.04%
Candel Therapeutics, Inc. Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.25
Actual
-$0.54
Surprise
-115.31%
LENZ Therapeutics, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.99
Actual
-$1.15
Surprise
-17.10%
Fennec Pharmaceuticals Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
$0.03
Actual
-$0.11
Surprise
-408.12%
Equillium, Inc. Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.06
Actual
-$0.04
Surprise
+35.28%
FAQ
What were AYTU BioPharma, Inc. Common Stock's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, AYTU BioPharma, Inc. Common Stock reported EPS of -$1.05, missing estimates by -71.57%, and revenue of $15.16M, 22.12% above expectations.
How did the market react to AYTU BioPharma, Inc. Common Stock's Q2 2026 earnings?
The stock price moved down -10.31%, changed from $2.62 before the earnings release to $2.35 the day after.
When is AYTU BioPharma, Inc. Common Stock expected to report next?
The next earning report is scheduled for May 12, 2026.
What are the forecasts for AYTU BioPharma, Inc. Common Stock's next earnings report?
Based on 5
analysts, AYTU BioPharma, Inc. Common Stock is expected to report EPS of -$0.57 and revenue of $13.31M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement